Medical Program: How Immune Checkpoint Inhibitors Changed the Therapeutic Landscape for NSCLC

How Immune Checkpoint Inhibitors Changed the Therapeutic Landscape for NSCLC

How Immune Checkpoint Inhibitors Changed the Therapeutic Landscape for NSCLC
RestartResume

Here’s why the introduction of immune checkpoint inhibitors to the non-small cell lung cancer treatment landscape is seen as a change for the better.

  • Overview

    Immune checkpoint inhibitors are now the standard of care for almost all of our patients with non-small cell lung cancer. And here to give us a look into how that’s impacted our patients and practices is Dr. Stephen Liu, Associate Professor of Medicine at the Lombardi Comprehensive Cancer Center of Georgetown University.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free